Capacity constraints are still a problem in the biomanufacturing industry, and almost six in 10 biomanufacturers are today facing at least minor constraints at some stage of manufacturing, according to data released in our 10th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production1. But contract manufacturing organizations (CMOs) appear to be less afflicted by significant constraint issues than biotherapeutic developers, and it may well be that a focus on downstream...